Iressa as Second Line Therapy in Advanced NSCLC-Asia

NCT00478049 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

163

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Gefitinib
DRUG: Docetaxel

Sponsor

AstraZeneca